Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria

Current Opinion in Pharmacology

Volumn 9, Issue 5, 2009, Pages 566-570

  Palliyil, Soumya ^a   Broadbent, Ian D ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AERUCIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIAL VACCINE; F 429; FLAGELLIN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; LIVE VACCINE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAB166; PERTUSSIS VACCINE; POLYCLONAL ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; DENTAL CARIES; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; KERATITIS; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; YERSINIA INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 70349519358     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.07.007     Document Type: Review

References (35)

1. Gould I.M. The epidemiology of antibiotic resistance. Int J Antimicrob Agents 32 Suppl. 1 (2008) S2-S9
2. Bebbington C., and Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 19 (2008) 613-619. This review concentrates on antibody therapeutics for both Gram negative and Gram-positive organisms.
3. Cegelski L., Marshall G.R., Eldridge G.R., and Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6 (2008) 17-27
4. Pai J.C., Sutherland J.N., and Maynard J.A. Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov 4 (2009) 1-17
5. Mukherjee J., Chios K., Fishwild D., Hudson D., O'Donnell S., Rich S.M., Donohue-Rolfe A., and Tzipori S. Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun 70 (2002) 5896-5899
6. Mukherjee J., Chios K., Fishwild D., Hudson D., O'Donnell S., Rich S.M., Donohue-Rolfe A., and Tzipori S. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun 70 (2002) 612-619
7. Krautz-Peterson G., Chapman-Bonofiglio S., Boisvert K., Feng H., Herman I.M., Tzipori S., and Sheoran A.S. Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun 76 (2008) 1931-1939
8. Akiyoshi D.E., Rich C.M., O'Sullivan-Murphy S., Richard L., Dilo J., Donohue-Rolfe A., Sheoran A.S., Chapman-Bonofiglio S., and Tzipori S. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infect Immun 73 (2005) 4054-4061
9. Singh Y., Palombo M., and Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 15 (2008) 1802-1826
10. Szynol A., de Haard J.J., Veerman E.C., de Soet J.J., and van Nieuw Amerongen A.V. Design of a peptibody consisting of the antimicrobial peptide dhvar5 and a llama variable heavy-chain antibody fragment. Chem Biol Drug Des 67 (2006) 425-431
11. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7 (2007) 715-725
12. Fick Jr. R.B., Baltimore R.S., Squier S.U., and Reynolds H.Y. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis 151 (1985) 589-598
13. Kruger C., Hultberg A., Marcotte H., Hermans P., Bezemer S., Frenken L.G., and Hammarstrom L. Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol 72 (2006) 732-737
14. Saerens D., Ghassabeh G.H., and Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 8 (2008) 600-608
15. Wentworth Jr. P., Wentworth A.D., Zhu X., Wilson I.A., Janda K.D., Eschenmoser A., and Lerner R.A. Evidence for the production of trioxygen species during antibody-catalyzed chemical modification of antigens. Proc Natl Acad Sci U S A 100 (2003) 1490-1493
16. Barnea Y., Carmeli Y., Neville L.F., Kahel-Reifer H., Eren R., Dagan S., and Navon-Venezia S. Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model. Burns 35 (2008) 390-396
17. Barnea Y., Carmeli Y., Gur E., Kuzmenko B., Gat A., Neville L.F., Eren R., Dagan S., and Navon-Venezia S. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model. Plast Reconstr Surg 117 (2006) 2284-2291
18. Hemachandra S., Kamboj K., Copfer J., Pier G., Green L.L., and Schreiber J.R. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infect Immun 69 (2001) 2223-2229
19. Lai Z., Kimmel R., Petersen S., Thomas S., Pier G., Bezabeh B., Luo R., and Schreiber J.R. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23 (2005) 3264-3271
20. Zaidi T., and Pier G.B. Prophylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infection. Infect Immun 76 (2008) 4720-4725
21. Pier G.B., Boyer D., Preston M., Coleman F.T., Llosa N., Mueschenborn-Koglin S., Theilacker C., Goldenberg H., Uchin J., Priebe G.P., et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 173 (2004) 5671-5678
22. Hussein A.H., Davis E.M., Halperin S.A., and Lee S.F. Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin. Infect Immun 75 (2007) 5476-5482
23. Chancey C.J., Khanna K.V., Seegers J.F., Zhang G.W., Hildreth J., Langan A., and Markham R.B. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 176 (2006) 5627-5636
24. Kruger C., Hultberg A., van Dollenweerd C., Marcotte H., and Hammarstrom L. Passive immunization by lactobacilli expressing single-chain antibodies against Streptococcus mutans. Mol Biotechnol 31 (2005) 221-231
25. Dowling T.C., Chavaillaz P.A., Young D.G., Melton-Celsa A., O'Brien A., Thuning-Roberson C., Edelman R., and Tacket C.O. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 49 (2005) 1808-1812
26. Baer M., Sawa T., Flynn P., Luehrsen K., Martinez D., Wiener-Kronish J.P., Yarranton G., and Bebbington C. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 77 (2009) 1083-1090
27. Imamura Y., Yanagihara K., Fukuda Y., Kaneko Y., Seki M., Izumikawa K., Miyazaki Y., Hirakata Y., Sawa T., Wiener-Kronish J.P., et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 29 (2007) 965-968
28. Hill J., Eyles J.E., Elvin S.J., Healey G.D., Lukaszewski R.A., and Titball R.W. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 74 (2006) 3068-3070
29. Eyles J.E., Butcher W.A., Titball R.W., and Hill J. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity. Vaccine 25 (2007) 7301-7306
30. Kaufmann G.F., Park J., and Janda K.D. Bacterial quorum sensing: a new target for anti-infective immunotherapy. Expert Opin Biol Ther 8 (2008) 719-724
31. Miyairi S., Tateda K., Fuse E.T., Ueda C., Saito H., Takabatake T., Ishii Y., Horikawa M., Ishiguro M., Standiford T.J., et al. Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J Med Microbiol 55 Pt 10 (2006) 1381-1387
32. Kaufmann G.F., Sartorio R., Lee S.H., Mee J.M., Altobell L.J., Kujawa D.P., Jeffries E., Clapham B., Meijler M.M., and Janda K.D. Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc 128 (2006) 2802-2803
33. Kaufmann G.F., Park J., Mee J.M., Ulevitch R.J., and Janda K.D. The quorum quenching antibody RS2-1G9 protects macrophages from the cytotoxic effects of the Pseudomonas aeruginosa quorum sensing signalling molecule N-3-oxo-dodecanoyl-homoserine lactone. Mol Immunol 45 (2008) 2710-2714
34. Zak O., Sande M.A., and O'Reilly T. Introduction: the role of animal models in the evaluation of new antibodies. In: Zak O., and Sande M.O. (Eds). Handbook of Experimental Models of Infection (1999), Academic Press, London xxi-xxiii
35. Doring G., and Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26 (2008) 1011-1024. Highlights the difficulties in developing anti-Pseudomonal vaccines and monoclonal antibodies, and performing clinical trials.